The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index, and 1 are not checked yet.
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Open accessPublished version of a preprint
Abstract
The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein 1-5 show promise therapeutically and are being evaluated clinically 6-8. Here, to identify the structural correlates of SARS-CoV-2 neutralization, we solved eight new structures of distinct COVID-19 human neutralizing antibodies 5 in complex with the SARS-CoV-2 spike trimer or RBD. Structural comparisons allowed us to classify the antibodies into categories: (1) neutralizing antibodies encoded by the VH3-53 gene segment with short CDRH3 loops that block ACE2 and bind only to 'up' RBDs; (2) ACE2-blocking neutralizing antibodies that bind both up and 'down' RBDs and can contact adjacent RBDs; (3) neutralizing antibodies that bind outside the ACE2 site and recognize both up and down RBDs; and (4) previously described antibodies that do not block ACE2 and bind only to up RBDs 9. Class 2 contained four neutralizing antibodies with epitopes that bridged RBDs, including a VH3-53 antibody that used a long CDRH3 with a hydrophobic tip to bridge between adjacent down RBDs, thereby locking the spike into a closed conformation. Epitope and paratope mapping revealed few interactions with host-derived N-glycans and minor contributions of antibody somatic hypermutations to epitope contacts. Affinity measurements and mapping of naturally occurring and in vitro-selected spike mutants in 3D provided insight into the potential for SARS-CoV-2 to escape from antibodies elicited during infection or delivered therapeutically. These classifications and structural analyses provide rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use, and provide insight into immune responses against SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, antibodies that share the same combination of IGHV and IGLV genes in vaccinees comprised 39% of all the clonal sequences (Extended Data Fig. 4b) and 59% when combined with naturally infected individuals7,8 (Fig. 2f), and some of these antibodies were nearly identical (Extended Data Table 3 and 4).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The T478K mutation in the RBD is unique to the Delta variant and falls within the epitope region of potent neutralizing monoclonal antibodies categorized as 'Class1' 17”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredIn the citing paper
“As expected, plasma neutralizing activity was directly correlated to anti-S and -RBD binding titers in ELISAs7,8 (Fig. 1c, d, and Extended Data Fig. 2a–d).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Moreover, the plasma neutralizing activity, and the relative numbers of RBD-specific memory B cells were equivalent to individuals who recovered from natural infection7,8.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Although circulating antibodies derived from plasma cells wane over time, long-lived immune memory can persist in expanded clones of memory B cells7,20.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“As seen in natural infection, a majority of the antibodies tested (9/17) were at least ten-fold less effective against pseudotyped viruses carrying the E484K mutation7,12,29.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“In anti-RBD ELISAs the mean half-maximal effective concentration (EC50) was higher than that observed in infected individuals after 6.2 months but not significantly different from antibodies obtained 1.3 months after infection (Extended Data Fig. 6a, and Table 5 and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Class 1 and 2 antibodies are among the most potent and also the most abundant antibodies7,8,21,22,25,39.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“Consistent with the plasma neutralization results, the geometric mean neutralization half-maximal inhibitory concentration of the Pfizer-BioNTech and Moderna vaccinee antibodies were not significantly different from each other or to antibody collections obtained from naturally infected individuals 1.3 or 6.2 months after infection (Fig. 3a and 7,8).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [7]
In the citing paper
“In contrast to the earlier time point, 13 of 15 neutralizing antibodies obtained after 12 months interfered only with C121, a class 2 antibody3,23 (Fig. 4c, Extended Data Fig. 9).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [23]
In the citing paper
“Residue S477 is close to the receptor binding site (Fig ED2) and part of the epitope recognized by the S2E12 and C102 neutralizing antibodies 17,18 .”
From Spread of a SARS-CoV-2 variant through Europe in the summer of 2020 (2021) · cites this paper as [17]
In the citing paper
“a potent Ab that can recognize both “up” and “down” SARS-CoV-2 RBD conformations [41].”
From Deep geometric representations for modeling effects of mutations on protein-protein binding affinity (2021) · cites this paper as [41]
In the citing paper
“Importantly, our spike did not contain R346K, which has been observed at relatively low frequency (<10%) within the Omicron lineage, but which is known to mediate escape from class 3 neutralizing monoclonal antibodies such as AZD1061/cilgavimab (Barnes et al., 2020; Dong et al., 2021; Greaney et al., 2021b).”
From mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2022) · cites this paper as Barnes et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Cited by
Sorted by citations
Items 101–200 of 1,004
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
Wang, K., Jia, Z., Bao, L., Wang, L., Cao, L., Chi, H., Hu, Y., Li, Q., Zhou, Y., Jiang, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-04466-x · Cited by 172
Prolonged evolution of the human B cell response to SARS-CoV-2 infection
Sakharkar, M., Rappazzo, C. G., Wieland-Alter, W. F., Hsieh, C.-L., Wrapp, D., Esterman, E. S., Kaku, C. I., Wec, A. Z., Geoghegan, J. C., McLellan, J. S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg6916 · Cited by 174
Defining the risk of SARS-CoV-2 variants on immune protection
DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04690-5 · Cited by 168
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
Zhou, T., Wang, L., Misasi, J., Pegu, A., Zhang, Y., Harris, D. R., Olia, A. S., Talana, C. A., Yang, E. S., Chen, M., et al. (2022) · Science · doi:10.1126/science.abn8897 · Cited by 163
Lateral flow assays for viruses diagnosis: Up-to-date technology and future prospects
Ince, B., & Sezgintürk, M. K. (2022) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2022.116725 · Cited by 179
Wang, Q., Guo, Y., Bowen, A. D., Mellis, I. A., Valdez, R., Gherasim, C., Gordon, A. L., Liu, L., & Ho, D. D. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.01.014 · Cited by 170
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Dopico, X. C., Ols, S., Loré, K., & Hedestam, G. B. K. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 172
Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients
Li, Y., Ma, M., Lei, Q., Wang, F., Hong, W., Lai, D., Hou, H., Xu, Z., Zhang, B., Chen, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108915 · Cited by 161
Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination
Schaefer-Babajew, D. J., Wang, Z., Muecksch, F., Cho, A., Loewe, M., Cipolla, M., Raspe, R., Johnson, B., Canis, M., DaSilva, J., et al. (2022) · Nature · doi:10.1038/s41586-022-05609-w · Cited by 172
Self-citationAn Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain
Wu, N. C., Yuan, M., Liu, H., Lee, C.-C. D., Zhu, X., Bangaru, S., Torres, J. L., Caniels, T. G., Brouwer, P. J. M., van Gils, M. J., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108274 · Cited by 158
Better, Faster, Cheaper: Recent Advances in Cryo–Electron Microscopy
Chua, E. Y. D., Mendez, J. H., Rapp, M., Ilca, S. L., Tan, Y. Z., Maruthi, K., Kuang, H., Zimanyi, C. M., Cheng, A., Eng, E. T., et al. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-110705 · Cited by 173
Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1
Jian, F., Wang, J., Yisimayi, A., Song, W., Xu, Y., Chen, X., Niu, X., Yang, S., Yu, Y., Wang, P., et al. (2024) · Nature · doi:10.1038/s41586-024-08315-x · Cited by 169
Neutralization, effector function and immune imprinting of Omicron variants
Addetia, A., Piccoli, L., Case, J. B., Park, Y., Beltramello, M., Guarino, B., Dang, H. V., de Melo, G. D., Pinto, D., Sprouse, K. R., et al. (2023) · Nature · doi:10.1038/s41586-023-06487-6 · Cited by 179
Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
Watanabe, Y., Mendonça, L., Allen, E. R., Howe, A., Lee, M., Allen, J. D., Chawla, H., Pulido, D., Donnellan, F. R., Davies, H. D., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00080 · Cited by 155
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects
Wheeler, S., Shurin, G. V., Yost, M., Anderson, A., Pinto, L., Wells, A. H., & Shurin, M. R. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00341-21 · Cited by 156
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity
Rosa, A., Pye, V. E., Graham, C., Muir, L., Seow, J., Ng, K. W., Cook, N., Rees-Spear, C., Parker, E. L., dos Santos, M. S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg7607 · Cited by 142
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galão, R. P., Dupont, L., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.023 · Cited by 155
Zhou, P.-P., Song, G., Liu, H., Yuan, M., He, W., Beutler, N., Zhu, X., Tse, L. V., Martinez, D. R., Schäfer, A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.02.005 · Cited by 154
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion
Ferreira, I. A. T. M., Kemp, S. A., Datir, R., Saito, A., Meng, B., Rakshit, P., Takaori-Kondo, A., Kosugi, Y., Uriu, K., Kimura, I., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab368 · Cited by 151
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al. (2021) · doi:10.1101/2021.01.26.21250224 · Cited by 651
“All three amino acid residues in the RBD that carry mutations in 501Y.V2 interact directly with the human angiotensin-converting enzyme 2 (hACE2) receptor and form part of the epitopes for hACE2-blocking NAbs [7].”
BackgroundInfluentialProtective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Xu, K., Gao, P., Liu, S., Lu, S., Lei, W., Zheng, T., Liu, X., Xie, Y., Zhao, Z., Guo, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.029 · Cited by 149
Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function
Yang, T., Yu, P., Chang, Y., Liang, K.-H., Tso, H.-C., Ho, M., Wy, C., Lin, H.-T., Wu, H., & Hsu, S. D. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00652-z · Cited by 167
An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain
Greaney, A. J., Starr, T. N., & Bloom, J. D. (2022) · Virus Evolution · doi:10.1093/ve/veac021 · Cited by 147
Cao, Y., Yisimayi, A., Bai, Y., Huang, W., Li, X., Zhang, Z., Yuan, T., An, R., Wang, J., Xiao, T., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00514-9 · Cited by 140
Antibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 150
Self-citationMoodley, A., Stegger, M., BAĞCIGİL, A. F., Baptiste, K. E., Loeffler, A., Lloyd, D. H., Williams, N. J., Leonard, N., Abbott, Y., Skov, R. L., et al. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl394 · Cited by 146
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice
Pymm, P., Adair, A., Chan, L., Cooney, J. P., Mordant, F. L., Allison, C. C., López, E., Haycroft, E. R., O’Neill, M. T., Tan, L. L., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101918118 · Cited by 137
Yin, R., & Pierce, B. G. (2024) · Protein Science · doi:10.1002/pro.4865 · Cited by 145
Wang, Z., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H.-H., Ramos, V., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.003 · Cited by 145
Self-citationEvolutionary trajectory of SARS-CoV-2 and emerging variants
Singh, J., Pandit, P., McArthur, A. G., Banerjee, A., & Mossman, K. L. (2021) · Virology Journal · doi:10.1186/s12985-021-01633-w · Cited by 150
Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2Preprint
Liu, L., Iketani, S., Guo, Y., Chan, J. F., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472719 · Cited by 142
Hassan, A. O., Feldmann, F., Zhao, H., Curiel, D. T., Okumura, A., Tang-Huau, T.-L., Case, J. B., Meade-White, K. D., Callison, J. A., Chen, R. E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100230 · Cited by 137
Deep geometric representations for modeling effects of mutations on protein-protein binding affinity
Liu, X., Luo, Y., Li, P., Song, S., & Peng, J. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009284 · Cited by 140
SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment
Li, D., Sempowski, G. D., Saunders, K. O., Acharya, P., & Haynes, B. F. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-113838 · Cited by 134
Review: Roles of human serum albumin in prediction, diagnoses and treatment of COVID-19
Rabbani, G., & Ahn, S. N. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.095 · Cited by 139
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
Kleanthous, H., Silverman, J. M., Makar, K. W., Yoon, I.-K., Jackson, N. M., & Vaughn, D. W. (2021) · npj Vaccines · doi:10.1038/s41541-021-00393-6 · Cited by 139
Spike deep mutational scanning helps predict success of SARS-CoV-2 clades
Dadonaite, B., Brown, J. T., McMahon, T. E., Farrell, A. G., Figgins, M. D., Asarnow, D. E., Stewart, C., Lee, J., Logue, J., Bedford, T., et al. (2024) · Nature · doi:10.1038/s41586-024-07636-1 · Cited by 145
Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species
Liu, K., Pan, X., Li, L., Yu, F., Zheng, A., Du, P., Han, P., Meng, Y., Zhang, Y., Wu, L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.031 · Cited by 136
Moriyama, S., Adachi, Y., Sato, T., Tonouchi, K., Sun, L., Fukushi, S., Yamada, S., Kinoshita, H., Nojima, K., Kanno, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.015 · Cited by 140
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
Gasparo, R. D., Pedotti, M., Simonelli, L., Nickl, P., Muecksch, F., Cassaniti, I., Percivalle, E., Lorenzi, J. C. C., Mazzola, F., Magrì, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03461-y · Cited by 134
Self-citationRecall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection
Kaku, C. I., Bergeron, A. J., Ahlm, C., Normark, J., Sakharkar, M., Forsell, M. N. E., & Walker, L. M. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq3511 · Cited by 135
Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains
Rella, S. A., Kulikova, Y. A., Dermitzakis, E. T., & Kondrashov, F. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-95025-3 · Cited by 139
Li, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S. Y., Tauzin, A., Gasser, R., Vézina, D., Anand, S. P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110210 · Cited by 128
Ao, D., He, X., Hong, W., & Wei, X. (2023) · MedComm · doi:10.1002/mco2.239 · Cited by 128
SARS-CoV-2 evolution in the Omicron era
Roemer, C., Sheward, D. J., Hisner, R., Gueli, F., Sakaguchi, H., Frohberg, N., Schoenmakers, J., Sato, K., O’Toole, Á., Rambaut, A., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01504-w · Cited by 130
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429Preprint
McCallum, M., Bassi, J., Marco, A. D., Chen, A., Walls, A. C., di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437925 · Cited by 128
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Hassan, A. O., Shrihari, S., Gorman, M. J., Ying, B., Yuan, D., Raju, S., Chen, R. E., Dmitriev, I. P., Kashentseva, E. A., Adams, L. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109452 · Cited by 131
Zhang, Q., Ju, B., Ge, J., Chan, J. F., Cheng, L., Wang, R., Huang, W., Fang, M., Chen, P., Zhou, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24514-w · Cited by 114
Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
Mittal, A., Khattri, A., & Verma, V. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010260 · Cited by 124
Jian, F., Feng, L., Yang, S., Yu, Y., Wang, L., Song, W., Yisimayi, A., Chen, X., Xu, Y., Wang, P., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011868 · Cited by 124
Protein N-myristoylation: functions and mechanisms in control of innate immunity
Wang, B., Dai, T., Sun, W., Wei, Y., Ren, J., Zhang, L., Zhang, M., & Zhou, F. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00663-2 · Cited by 128
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
Bates, T. A., Leier, H. C., Lyski, Z. L., McBride, S. K., Coulter, F. J., Weinstein, J. B., Goodman, J. R., Lu, Z., Siegel, S. A. R., Sullivan, P. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25479-6 · Cited by 115
Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike
Tong, P., Gautam, A. K., Windsor, I. W., Travers, M. E., Chen, Y., Garcia, N., Whiteman, N. B., McKay, L. G. A., Storm, N., Malsick, L. E., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.025 · Cited by 115
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 121
Singh, J., Samal, J., Kumar, V., Sharma, J., Agrawal, U., Ehtesham, N. Z., Sundar, D., Rahman, S. A., Hira, S., & Hasnain, S. E. (2021) · Viruses · doi:10.3390/v13030439 · Cited by 118
A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice
Martinez, D. R., Schäfer, A., Gobeil, S., Li, D., la Cruz, G. D., Parks, R., Lu, X., Barr, M., Stalls, V., Janowska, K., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj7125 · Cited by 137
Tortorici, M. A., Addetia, A., Seo, A. J., Brown, J. T., Sprouse, K., Logue, J., Clark, E., Franko, N., Chu, H. Y., & Veesler, D. (2024) · Immunity · doi:10.1016/j.immuni.2024.02.016 · Cited by 127
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsPreprint
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.30.442182 · Cited by 118
Zhang, G., Cong, Y., Liu, F., Sun, J., Zhang, J., Cao, G., Zhou, L., Yang, W., Song, Q., Wang, F., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01177-2 · Cited by 120
Omicron SARS-CoV-2 variant: What we know and what we don’t
Ferré, V. M., Peiffer‐Smadja, N., Visseaux, B., Descamps, D., Ghosn, J., & Charpentier, C. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100998 · Cited by 119
Zahradník, J., Marciano, S., Shemesh, M., Zoler, E., Chiaravalli, J., Meyer, B., Rudich, Y., Dym, O., Elad, N., & Schreiber, G. (2021) · doi:10.1101/2021.01.06.425392 · Cited by 458
Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y. E., Huey‐Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109760 · Cited by 99
Self-citationMutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Mengist, H. M., Kombe, A. J. K., Mekonnen, D. S., Abebaw, A., Getachew, M., & Jin, T. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101533 · Cited by 115
Martin, D. P., Lytras, S., Lucaci, A. G., Maier, W., Grüning, B. A., Shank, S. D., Weaver, S., MacLean, O. A., Orton, R. J., Lemey, P., et al. (2022) · Molecular Biology and Evolution · doi:10.1093/molbev/msac061 · Cited by 129
Neutralizing antibodies targeting SARS-CoV-2 spike protein
Shi, X., Yu, L., Yan, L., Guang, Y., & Qiang, M. (2020) · Stem Cell Research · doi:10.1016/j.scr.2020.102125 · Cited by 114
Caniels, T. G., Bontjer, I., van der Straten, K., Poniman, M., Burger, J. A., Appelman, B., Lavell, A. H. A., Oomen, M., Godeke, G.-J., Valle, C., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj5365 · Cited by 107
Wang, Y., Yuan, M., Lv, H., Peng, J., Wilson, I. A., & Wu, N. C. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.019 · Cited by 119
Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
Wang, Q., Iketani, S., Li, Z., Guo, Y., Yeh, A. Y., Liu, M., Yu, J., Sheng, Z., Huang, Y., Liu, L., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.09.002 · Cited by 108
SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine
Kotaki, R., Adachi, Y., Moriyama, S., Onodera, T., Fukushi, S., Nagakura, T., Tonouchi, K., Terahara, K., Sun, L., Takano, T., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8590 · Cited by 115
Cryo-EM structure of the SARS-CoV-2 Omicron spike
Cerutti, G., Guo, Y., Liu, L., Liu, L., Zhang, Z., Luo, Y., Huang, Y., Wang, H. H., Ho, D. D., Sheng, Z., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110428 · Cited by 108
Jordan, S. C. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13582 · Cited by 113
Sabatino, J. J., Mittl, K., Rowles, W. M., McPolin, K., Rajan, J. V., Laurie, M. T., Zamecnik, C. R., Dandekar, R., Alvarenga, B. D., Loudermilk, R. P., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156978 · Cited by 105
Brockman, M. A., Mwimanzi, F. M., Lapointe, H. R., Sang, Y., Agafitei, O., Cheung, P. K., Ennis, S., Ng, K., Basra, S., Lim, L. Y., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab592 · Cited by 108
Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86
Lasrado, N., Collier, A.-R. Y., Hachmann, N. P., Miller, J. J., Rowe, M., Schonberg, E., Rodrigues, S. L., LaPiana, A., Patio, R. C., Anand, T., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.10.051 · Cited by 105
Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infectionPreprint
Karim, F., Moosa, M.-Y. S., Gosnell, B., Cele, S., Giandhari, J., Pillay, S., Tegally, H., Wilkinson, E., San, J., Msomi, N., et al. (2021) · medRxiv · doi:10.1101/2021.06.03.21258228 · Cited by 105
Tao, K., Tzou, P. L., Nouhin, J., Bonilla, H. F., Jagannathan, P., & Shafer, R. W. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-21 · Cited by 109
Gale, E. C., Powell, A. E., Roth, G. A., Meany, E. L., Yan, J., Ou, B. S., Grosskopf, A. K., Adamska, J. Z., Picece, V. C. T. M., d’Aquino, A. I., et al. (2021) · Advanced Materials · doi:10.1002/adma.202104362 · Cited by 107
Current status of therapeutic monoclonal antibodies against SARS-CoV-2
Kumar, S., Chandele, A., & Sharma, A. K. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009885 · Cited by 104
Antiviral Drug Discovery for the Treatment of COVID-19 Infections
Ng, T. I., Correia, I., Seagal, J., DeGoey, D. A., Schrimpf, M. R., Hardee, D. J., Noey, E. L., & Kati, W. M. (2022) · Viruses · doi:10.3390/v14050961 · Cited by 101
Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant
Khan, K., Lustig, G., Roemer, C., Reedoy, K., Jule, Z., Karim, F., Ganga, Y., Bernstein, M. P., Baig, Z., Jackson, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43703-3 · Cited by 93
Deshpande, A. A., Harris, B. D., Martínez‐Sobrido, L., Kobie, J. J., & Walter, M. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691715 · Cited by 94
Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
Sasso, B. L., Giglio, R. V., Vidali, M., Scazzone, C., Bivona, G., Gambino, C. M., Ciaccio, A. M., Agnello, L., & Ciaccio, M. (2021) · Diagnostics · doi:10.3390/diagnostics11071135 · Cited by 95
VanBlargan, L. A., Adams, L. J., Liu, Z., Chen, R. E., Gilchuk, P., Raju, S., Smith, B. K., Zhao, H., Case, J. B., Winkler, E. S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.016 · Cited by 87
Mannar, D., Saville, J. W., Zhu, X. Q., Srivastava, S. S., Berezuk, A., Zhou, S., Tuttle, K. S., Kim, A., Li, W., Dimitrov, D. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110156 · Cited by 90
ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
Hoffmann, M. A. G., Yang, Z., Huey‐Tubman, K. E., Cohen, A. A., Gnanapragasam, P. N. P., Nakatomi, L. M., Storm, K. N., Moon, W. J., Lin, P. J. C., West, A. P., et al. (2023) · Cell · doi:10.1016/j.cell.2023.04.024 · Cited by 104
Self-citationB cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
Scheid, J. F., Barnes, C. O., Eraslan, B., Hudak, A., Keeffe, J. R., Cosimi, L. A., Brown, E., Muecksch, F., Weisblum, Y., Zhang, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.032 · Cited by 90
Self-citationHarbison, A. M., Fogarty, C. A., Phung, T. K., Satheesan, A., Schulz, B. L., & Fadda, E. (2021) · Chemical Science · doi:10.1039/d1sc04832e · Cited by 86
Retrospective Evaluation of Partial Parenteral Nutrition in Dogs and Cats
Chan, D. L., Freeman, L. M., Labato, M. A., & Rush, J. E. (2002) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2002.tb01262.x · Cited by 93
Lv, H., Dao, F., Zulfiqar, H., & Lin, H. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab244 · Cited by 91
The success of SARS-CoV-2 vaccines and challenges ahead
Subbarao, K. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.016 · Cited by 92
Silva, R. P., Huang, Y., Nguyen, A. W., Hsieh, C., Olaluwoye, O. S., Kaoud, T. S., Wilen, R. E., Qerqez, A. N., Park, J., Khalil, A. M., et al. (2023) · eLife · doi:10.7554/elife.83710 · Cited by 86
Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York
West, A. P., Wertheim, J. O., Wang, J. C., Vasylyeva, T. I., Havens, J. L., Chowdhury, M. A., Gonzalez, E., Fang, C. E., Lonardo, S. S. D., Hughes, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25168-4 · Cited by 134
Self-citationBoosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
Ying, B., Scheaffer, S. M., Whitener, B. M., Liang, C.-Y., Dmytrenko, O., Mackin, S., Wu, K., Lee, D. W., Avena, L. E., Chong, Z., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.037 · Cited by 109
Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2
Gao, K., Wang, R., Chen, J., Cheng, L., Frishcosy, J., Huzumi, Y., Qiu, Y., Schluckbier, T., Wei, X., & Wei, G. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00965 · Cited by 93
Wilhelm, A., Toptan, T., Pallas, C., Wolf, T., Goetsch, U., Gottschalk, R., Vehreschild, M. J. G. T., Ciesek, S., & Widera, M. (2021) · Viruses · doi:10.3390/v13091693 · Cited by 82
A structural view of the SARS-CoV-2 virus and its assembly
Hardenbrook, N. J., & Zhang, P. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.11.011 · Cited by 93
Urgency and necessity of Epstein-Barr virus prophylactic vaccines
Zhong, L., Krummenacher, C., Zhang, W., Hong, J., Feng, Q., Chen, Y., Zhao, Q., Zeng, M., Zeng, Y., Xu, M., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00587-6 · Cited by 88
Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants
Li, T., Xue, W., Zheng, Q., Song, S., Yang, C., Xiong, H., Zhang, S., Hong, M., Zhang, Y., Yu, H. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25997-3 · Cited by 72
Point-of-care diagnostics: recent developments in a pandemic age
Harpaldas, H., Arumugam, S., Rodriguez, C. C., Kumar, B. A., Shi, V. Y., & Sia, S. K. (2021) · Lab on a Chip · doi:10.1039/d1lc00627d · Cited by 82
Serological evidence of SARS‐CoV‐2 and co‐infections in stray cats in Spain
Villanueva‐Saz, S., Giner, J., Tobajas, A. P., Pérez, M. D., González‐Ramírez, A. M., Macías‐León, J., González, A. I., Verde, M., Yzuel, A., Hurtado‐Guerrero, R., et al. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14062 · Cited by 82
Metadata
- Authors
- Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., Robbiani, D. F., Nussenzweig, M. C., West, A. P., & Bjorkman, P. J.
- Affiliations
- California Institute of Technology (US)
- Institute for Research in Biomedicine (CH)
- Howard Hughes Medical Institute (US)
- ORCID
- Venue
- Nature
- Published
- 2020-10-12
- Volume
- 588
- Issue
- 7839
- Pages
- 682-687
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8092461
- OpenAlex
- W3092403777
- Cited by
- 1,599
- References
- 70
- Citations by year
- 2026: 94 · 2025: 121 · 2024: 181 · 2023: 267 · 2022: 448 · 2021: 440 · 2020: 35
- FWCI
- 39.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-02)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by-nc-nd)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- U.S. Department of Energy (P41GM103393, DE-AC02-)
- Burroughs Wellcome Fund
- George Mason University
- California Institute of Technology
- Wellcome Trust
- National Institutes of Health (AI138938, P01 AI138938-S1, AI150464)
- Office of Science (P41GM103393, DE-AC02)
- Beckman Institute, California Institute of Technology
- National Institute of General Medical Sciences (AI150464, P41GM103393)
- National Institute of Allergy and Infectious Diseases (P50AI150464, F30AI147579, P01AI138938)
- Basic Energy Sciences (DE-AC02, P41GM103393)
- Biological and Environmental Research (P41 GM103393)
- SLAC National Accelerator Laboratory (P41GM103393)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, spike protein receptor-binding domain, antibody-antigen complex structure, ACE2 receptor, epitope mapping, N-glycans, somatic hypermutation, antibody escape, avidity, antibody combination therapy, spike trimer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
